NCT02530970

Brief Summary

The objective of the SECURE Study is to actively gather additional information on the use of the CorMatrix® CanGaroo ECM® Envelope in a post market observational study.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
1,025

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Oct 2015

Typical duration for all trials

Geographic Reach
1 country

39 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 18, 2015

Completed
3 days until next milestone

First Posted

Study publicly available on registry

August 21, 2015

Completed
1 month until next milestone

Study Start

First participant enrolled

October 1, 2015

Completed
2.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2017

Completed
4 months until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2018

Completed
1.9 years until next milestone

Results Posted

Study results publicly available

March 11, 2020

Completed
Last Updated

July 21, 2023

Status Verified

July 1, 2023

Enrollment Period

2.2 years

First QC Date

August 18, 2015

Results QC Date

February 17, 2020

Last Update Submit

July 19, 2023

Conditions

Outcome Measures

Primary Outcomes (2)

  • Proportion of Subjects With ECM Related Adverse Events

    ECM related adverse events were collected at all study visits.

    Participants were followed for an average of 235.0 days.

  • Number of Participants With Major Pocket Infections

    Incidence of major pocket infection included those with cellulitis in the region of the CIED pocket with wound dehiscence, erosion or purulent drainage, 2) deep incisional or organ/space (pocket) surgical site infection, 3) persistent bacteremia or 4) endocarditis.

    Participants were followed for an average of 235.0 days.

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Subjects who have received CorMatrix® CanGaroo ECM® Envelope for an implantable electronic device placement.

You may qualify if:

  • Subjects who have received CorMatrix® CanGaroo ECM® Envelope for an implantable electronic device placement.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (39)

Advanced Cardiovascular, LLC

Alexander City, Alabama, 35010, United States

Location

Heart & Rhythm Solution

Chandler, Arizona, 85286, United States

Location

Cardiac Electrophysiology/St. Joseph

Phoenix, Arizona, 85006, United States

Location

Arizona Heart Rhythm Center

Phoenix, Arizona, 85016, United States

Location

Little Rock VA Clinic

Little Rock, Arkansas, 72205, United States

Location

Mercy Heart & Vascular

Rogers, Arkansas, 72758, United States

Location

Stockton Medical Center

Stockton, California, 95204, United States

Location

St. Joseph Heritage Medical Group

Tustin, California, 92780, United States

Location

Bay Pines VA

Bay Pines, Florida, 33744, United States

Location

Bethesda

Delray Beach, Florida, 33484, United States

Location

Florida Heart & Rhythm Specialists

Fort Lauderdale, Florida, 33308, United States

Location

Baptist Heart Specialists

Jacksonville, Florida, 32207, United States

Location

UF Health Jacksonville

Jacksonville, Florida, 32209, United States

Location

Cardiovascular Institute of NW Florida

Panama City, Florida, 32401, United States

Location

Baptist Healthcare Cardiology

Pensacola, Florida, 32501, United States

Location

Cardiology Associates

Albany, Georgia, 31701, United States

Location

Athens Cardiology Group

Athens, Georgia, 30606, United States

Location

North Georgia Heart Foundation

Gainesville, Georgia, 30501, United States

Location

Georgia Arrhythmia Consultants

Macon, Georgia, 31201, United States

Location

The Queen's Medical Center

Honolulu, Hawaii, 96813, United States

Location

Central DuPage Hospital

Winfield, Illinois, 60190, United States

Location

University of Michigan

Ann Arbor, Michigan, 48109, United States

Location

Wayne State University Physician Group

Detroit, Michigan, 48201, United States

Location

St. John Providence

Detroit, Michigan, 48236, United States

Location

Cardiology Institute of Michigan

Flint, Michigan, 48507, United States

Location

Advanced Cardiovascular Clinic

Flushing, Michigan, 48433, United States

Location

Sparrow Thoracic Cardiovascular Institute

Lansing, Michigan, 48912, United States

Location

HeartPlus Center

Jackson, Mississippi, 39216, United States

Location

Sanger Heart & Vascular

Concord, North Carolina, 28025, United States

Location

Carolina East Heart Center

New Bern, North Carolina, 28562, United States

Location

NC Heart & Vascular

Raleigh, North Carolina, 27610, United States

Location

Novant Health Winston-Salem Cardiology

Winston-Salem, North Carolina, 27103, United States

Location

University of Oregon Health Science Center

Portland, Oregon, 97239, United States

Location

Wellspan Heart & Vascular

York, Pennsylvania, 17405, United States

Location

AnMed Health Arrhythmia Specialists

Anderson, South Carolina, 29621, United States

Location

South Carolina Heart Center

Columbia, South Carolina, 29204, United States

Location

Carolina Heart Specialists

Lancaster, South Carolina, 29720, United States

Location

Carolina Cardiology Clinical Research

Rock Hill, South Carolina, 29732, United States

Location

UT Health Science Center - EP Heart

The Woodlands, Texas, 77384, United States

Location

Related Publications (1)

  • Deering TF, Catanzaro JN, Woodard DA. Physician antibiotic hydration preferences for biologic antibacterial envelopes during cardiac implantable device procedures. Front Cardiovasc Med. 2022 Dec 22;9:1006091. doi: 10.3389/fcvm.2022.1006091. eCollection 2022.

MeSH Terms

Conditions

Cardiovascular Diseases

Limitations and Caveats

It was single-arm study thereby precluding the possibility of direct comparisons with a control. Also, a longer follow-up would allow for the confirmation of the long-term efficacy of the CanGaroo envelope.

Results Point of Contact

Title
Clinical Director
Organization
Aziyo Biologics, Inc.

Study Officials

  • Andrew Green

    Corvivo Cardiovascular, Inc.

    STUDY DIRECTOR

Publication Agreements

PI is Sponsor Employee
No
Restriction Type
GT60
Restrictive Agreement
Yes

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 18, 2015

First Posted

August 21, 2015

Study Start

October 1, 2015

Primary Completion

December 1, 2017

Study Completion

April 1, 2018

Last Updated

July 21, 2023

Results First Posted

March 11, 2020

Record last verified: 2023-07

Locations